Latest Posts
TRIPS Council to discuss IP and the public interest in the context of Covid-19
The search for new treatments and vaccines needed to respond to the Covid-19 outbreak has laid bare some key issues around intellectual property (IP)...
Remdesivir developed country price announced
On 29, June 2020 Gilead announced its global price for developed countries for remdesivir, a medicine that has shown some effect in the treatment...
COVID-19 Technology Access Pool (C-TAP): A Promising Human Rights Approach
Authors: Katrina Perehudoff and Jennifer Sellin
This article is a reprint, and first appeared on 4 June 2020 in Health and Human Rights.
How do we...
Medicines Law & Policy welcomes WHO’s Solidarity Call to Action to realise equitable global...
The World Health Organization today with Costa Rica launched the "COVID-19 Technology Access Pool (C-TAP)" to ensure that knowledge, data and intellectual property are...
Price, profit and the Covid-19 health technology pool: The example of remdesivir
We cannot yet know the precise trajectory of the Covid-19 pandemic, nor which therapies or vaccines will eventually prove most effective in its treatment...
Watch the webinar on the WHO Covid-19 Technology Pool
On 14 May 2020, Medicines Law & Policy together with Health Action International, WEMOS, The Foundation for Pharmaceutical Accountability and Knowledge Ecology International held...
This work is licensed under